LM Advisors LLC Invests $25.95 Million in Liquidia Co. (NASDAQ:LQDA)

LM Advisors LLC bought a new stake in shares of Liquidia Co. (NASDAQ:LQDA) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 2,206,443 shares of the company’s stock, valued at approximately $25,948,000. Liquidia makes up about 4.3% of LM Advisors LLC’s holdings, making the stock its 5th largest position.

Several other institutional investors have also modified their holdings of the stock. Steward Partners Investment Advisory LLC acquired a new stake in shares of Liquidia in the fourth quarter valued at $59,000. EntryPoint Capital LLC acquired a new stake in shares of Liquidia during the 4th quarter worth about $154,000. Walleye Trading LLC boosted its holdings in shares of Liquidia by 54.7% in the 3rd quarter. Walleye Trading LLC now owns 13,201 shares of the company’s stock valued at $132,000 after buying an additional 4,670 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Liquidia in the 4th quarter valued at about $169,000. Finally, Arizona State Retirement System boosted its holdings in shares of Liquidia by 20.3% in the fourth quarter. Arizona State Retirement System now owns 15,888 shares of the company’s stock valued at $187,000 after acquiring an additional 2,685 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Trading Down 4.7 %

LQDA opened at $14.87 on Thursday. Liquidia Co. has a twelve month low of $8.26 and a twelve month high of $16.81. The stock has a market cap of $1.27 billion, a PE ratio of -9.12 and a beta of 0.07. The business’s 50 day moving average is $15.01 and its 200-day moving average is $12.34.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The business had revenue of $2.92 million for the quarter, compared to analyst estimates of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. As a group, analysts forecast that Liquidia Co. will post -1.51 EPS for the current year.

Insider Activity at Liquidia

In other news, General Counsel Russell Schundler sold 16,393 shares of the stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $193,109.54. Following the transaction, the general counsel now owns 573,478 shares in the company, valued at $6,755,570.84. This represents a 2.78 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Michael Kaseta sold 23,370 shares of the stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $275,298.60. Following the transaction, the chief financial officer now directly owns 401,755 shares in the company, valued at $4,732,673.90. The trade was a 5.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,245 shares of company stock worth $843,326. 30.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

LQDA has been the subject of a number of recent research reports. Needham & Company LLC increased their price objective on Liquidia from $19.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, March 20th. Scotiabank restated an “outperform” rating on shares of Liquidia in a research report on Thursday, March 20th. Wells Fargo & Company began coverage on Liquidia in a research note on Friday, December 20th. They set an “overweight” rating and a $20.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price on shares of Liquidia in a research note on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Liquidia currently has a consensus rating of “Buy” and a consensus target price of $26.63.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).